Prieur X.,Clinical Research Laboratories
Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids | Year: 2010
Accumulation of lipid metabolites within non-adipose tissues can induce chronic inflammation by promoting macrophage infiltration and activation. Oxidized and glycated lipoproteins, free fatty acids, free cholesterol, triacylglycerols, diacylglycerols and ceramides have long been known to induce cellular dysfunction through their pro-inflammatory and pro-apoptotic properties. Emerging evidence suggests that macrophage activation by lipid metabolites and further modulation by lipid signaling represents a common pathogenic mechanism underlying lipotoxicity in atherosclerosis, obesity-associated insulin resistance and inflammatory diseases related to metabolic syndrome such as liver steatosis and chronic kidney disease. In this review, we discuss the latest discoveries that support the role of lipids in modulating the macrophage phenotype in different metabolic diseases. We describe the common mechanisms by which lipid derivatives, through modulation of macrophage function, promote plaque instability in the arterial wall, impair insulin responsiveness and contribute to inflammatory liver, muscle and kidney disease. We discuss the molecular mechanism of lipid activation of pro-inflammatory pathways (JNK, NFκB) and the key roles played by the PPAR and LXR nuclear receptors-lipid sensors that link lipid metabolism and inflammation. © 2009 Elsevier B.V. All rights reserved.
News Article | December 12, 2016
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Enterprise Laboratory Informatics Market Analysis and Trends - Solutions and Chromatography Data Systems (CDS)), Application - Forecast to 2025" report to their offering. Some of the prominent trends that the market is witnessing include increasing business needs for Commercial Off the Shelf Systems, Using wearable mobile devices are enabling faster and immediate interaction, Improvements in RFID technology have led to smarter tracking of samples and devices for laboratory operations and Big Data analytics, mobile applications, SaaS and cloud services are leading to a technological boom in laboratory informatics. Based on Solutions the market is categorized into LIMS (Laboratory Information Management System), ELN (electronic Laboratory Notebooks), SDMS (Scientific Data Management System), Chromatography Data Systems (CDS), CAPA (Corrective Action & Prevention Action), Electronic Data Capture (EDC) and Clinical Data Management Systems (CDMS). Depending on the application the market is segmented by Healthcare, Finance, Legal and Life Sciences and clinics. The Life sciencs and clinics augment is further divided as Biobanks/Biorepositories , Molecular Diagnostics and Clinical Research Laboratories. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors. For more information about this report visit http://www.researchandmarkets.com/research/mgkw26/global_enterprise
News Article | December 14, 2016
Research and Markets has announced the addition of the "Global Enterprise Laboratory Informatics Market Analysis and Trends - Solutions and Chromatography Data Systems (CDS)), Application - Forecast to 2025" report to their offering. Some of the prominent trends that the market is witnessing include increasing business needs for Commercial Off the Shelf Systems, Using wearable mobile devices are enabling faster and immediate interaction, Improvements in RFID technology have led to smarter tracking of samples and devices for laboratory operations and Big Data analytics, mobile applications, SaaS and cloud services are leading to a technological boom in laboratory informatics. Based on Solutions the market is categorized into LIMS (Laboratory Information Management System), ELN (electronic Laboratory Notebooks), SDMS (Scientific Data Management System), Chromatography Data Systems (CDS), CAPA (Corrective Action & Prevention Action), Electronic Data Capture (EDC) and Clinical Data Management Systems (CDMS). Depending on the application the market is segmented by Healthcare, Finance, Legal and Life Sciences and clinics. The Life sciencs and clinics augment is further divided as Biobanks/Biorepositories , Molecular Diagnostics and Clinical Research Laboratories. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors. For more information about this report visit http://www.researchandmarkets.com/research/bx464n/global_enterprise
Ying W.,Shanghai JiaoTong University |
Xiong Z.-G.,Clinical Research Laboratories
Current Medicinal Chemistry | Year: 2010
Numerous studies have indicated oxidative stress as a key pathological factor in ischemic brain injury. One of the key links between oxidative stress and cell death is excessive activation of poly(ADP-ribose) polymerase-1 (PARP-1), which plays an important role in the ischemic brain damage in male animals. Multiple studies have also suggested that NAD + depletion mediates PARP-1 cytotoxicity, and NAD + administration can decrease ischemic brain injury. A number of recent studies have provided novel information regarding the mechanisms underlying the roles of oxidative stress and NAD +-dependent enzymes in ischemic brain injury. Of particular interest, there have been exciting progresses regarding the mechanisms underlying the roles of NADPH oxidase and PARP-1 in cerebral ischemia. For examples, it has been suggested that androgen signaling and binding of PARP-1 onto estrogen receptors could account for the intriguing findings that PARP-1 plays remarkably differential roles in the ischemic brain damage of male and female animals; and some studies have suggested casein kinase 2, copper-zinc superoxide dismutase, and estrogen signaling can modulate the expression and activity of NADPH oxidase. This review summarizes these important current advances, and proposes future perspectives for the studies on the roles of oxidative stress and NAD + in cerebral ischemia. It is increasingly likely that future studies on NAD- and NADPdependent enzymes, such as NADPH oxidase, PARP-1, and sirtuins, would expose novel mechanisms underlying the roles of oxidative stress in cerebral ischemia, and suggest new therapeutic strategies for treating the debilitating disease. © 2010 Bentham Science Publishers Ltd.
News Article | December 16, 2016
— The report "Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application (Neurology, Hematology, Rheumatology, Immunology) End User (Hospitals, Clinical Research Laboratories) - Global Forecast to 2021", The plasma fractionation market witnessed healthy growth during the last decade and is expected to grow at a CAGR of 6.7% between 2016 and 2021 to reach USD 26.07 Billion by 2021. Growth in this market can be attributed to factors such as rise in aging population worldwide, the increasing on and off-label use of immunoglobulin for various chronic diseases, increased diagnosis rate, and rise in the use of prophylactic treatment for bleeding and immune diseases. The global plasma fractionation market is segmented based on products, applications, end users, and regions. Based on products, the market is further segmented into immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors, and other plasma products. Based on application types, the market is further segmented into neurology, immunology, hematology, pulmonology, hemato-oncology, rheumatology, critical care, and other applications. On the basis of end users, the global plasma fractionation market is segmented into hospitals and clinics, clinical research laboratories, and academic institutes. Based on regions, the plasma fractionation market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. In 2015, immunoglobulin accounted for the largest share of the global plasma fractionation market. However, the protease inhibitors segment is expected to witness the highest growth in the next five years. The growth of protease inhibitors is mainly attributed to its increasing use for respiratory diseases and growing application in various diseases. On the basis of applications, the neurology segment accounted for the largest share of the global plasma fractionation market. The large share of this market segment is mainly due to factors such as increasing use of immunoglobulin in neurological diseases. In the end-user segment, hospitals and clinics accounted for the largest share of the plasma fractionation market and are expected to grow at the highest CAGR in next five years. This large share is due to the increasing use of plasma products for labeled and off-labeled use for the treatment of various diseases in hospitals and clinics. North America is the largest regional segment for plasma fractionation. The large share of this regional segment can be attributed increasing use of immunoglobulins in neurological diseases and increasing use of prophylaxis treatments for diagnosed patients, and the rising number of registered hemophilic patients in this region. However, the market in the Asia-Pacific region is expected to grow at the highest CAGR, owing to the rapid growth in the aging population, increasing use of albumin and immunoglobulin, and increasing number of hemophilic patients. CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), and Kedrion S.p.A (Italy) held the major share of the plasma fractionation market and will continue to dominate the market between 2016 and 2021. Other major players operating in this market are Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France). For more information, please visit http://www.marketsandmarkets.com/Market-Reports/plasma-fractionation-market-93798284.html
Al-Sabbagh M.,Imperial College London |
Lam E.W.-F.,Imperial College London |
Brosens J.J.,Clinical Research Laboratories
Molecular and Cellular Endocrinology | Year: 2012
Throughout the reproductive years, the rise and fall in ovarian hormones elicit in the endometrium waves of cell proliferation, differentiation, recruitment of inflammatory cells, apoptosis, tissue breakdown and regeneration. The activated progesterone receptor, a member of the superfamily of ligand-dependent transcription factors, is the master regulator of this intense tissue remodelling process in the uterus. Its activity is tightly regulated by interaction with cell-specific transcription factors and coregulators as well as by specific posttranslational modifications that respond dynamically to a variety of environmental and inflammatory signals. Endometriosis, a chronic inflammatory disorder, disrupts coordinated progesterone responses throughout the reproductive tract, including in the endometrium. This phenomenon is increasingly referred to as 'progesterone resistance'. Emerging evidence suggests that progesterone resistance in endometriosis is not just a consequence of perturbed progesterone signal transduction caused by chronic inflammation but associated with epigenetic chromatin changes that determine the intrinsic responsiveness of endometrial cells to differentiation cues. © 2011 Elsevier Ireland Ltd.
Brosens I.,Leuven Institute for Fertility and Embryology |
Brosens J.,Clinical Research Laboratories |
Benagiano G.,University of Rome La Sapienza
Human Reproduction | Year: 2013
We elaborate on a new theory to explain pelvic endometriosis, including endometriosis in premenarcheal girls, based on the finding that the neonatal endometrium can display secretory activity immediately after birth and, in some cases, changes analogous to those seen at menstruation in adults. The neonatal uterus is therefore capable of shedding its endometrium. Indeed, occult vaginal bleeding occurs in a majority of neonates, although overt bleeding is estimated to occur in only 5% of neonates. This may be due to functional plugging of the endocervical canal in the neonate, which in turn would promote retrograde flux of endometrial cells contained in menstrual debris. Ectopic endometrial implantation in a newborn with hydrometrocolpos has been documented. These data, coupled with the observation of a significantly increased risk of endometriosis in adolescents with cervical outflow obstruction and patent Fallopian tubes, indicate that endometriosis, especially in children and young adolescents, may originate from retrograde uterine bleeding soon after birth. © 2013 © The Author 2013. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: email@example.com.
Macpherson A.J.,Clinical Research Laboratories |
McCoy K.D.,Clinical Research Laboratories
Mucosal Immunology | Year: 2015
An appreciation of the importance of interactions between microbes and multicellular organisms is currently driving research in biology and biomedicine. Many human diseases involve interactions between the host and the microbiota, so investigating the mechanisms involved is important for human health. Although microbial ecology measurements capture considerable diversity of the communities between individuals, this diversity is highly problematic for reproducible experimental animal models that seek to establish the mechanistic basis for interactions within the overall host-microbial superorganism. Conflicting experimental results may be explained away through unknown differences in the microbiota composition between vivaria or between the microenvironment of different isolated cages. In this position paper, we propose standardised criteria for stabilised and defined experimental animal microbiotas to generate reproducible models of human disease that are suitable for systematic experimentation and are reproducible across different institutions. © 2015 Society for Mucosal Immunology.
James G.,Clinical Research Laboratories
Spine | Year: 2016
STUDY DESIGN.: Longitudinal case control animal model. OBJECTIVE.: To investigate effects of mesenchymal stem cell (MSC) treatment on multifidus muscle remodeling after intervertebral disc (IVD) lesion. SUMMARY OF BACKGROUND DATA.: Lesion and degeneration of IVDs causes structural remodeling of the multifidus muscle. Pro-inflammatory cytokines are thought to contribute. MSC-treatment restores IVD health after lesion but its effects on surrounding tissues remains unknown. Using an animal model of IVD degeneration, we assessed the effects of MSC-treatment of IVDs on the structural remodeling and cytokine expression within the multifidus muscle. METHODS.: An anterolateral lesion was performed on the L1–2, L3–4 and L5–6 IVDs in sheep. At either 4 (early treatment) or 12 (late treatment) weeks after IVD lesion, MSCs were injected into the lesioned IVD. Multifidus muscle was harvested from L2 (gene expression analysis) and L4 (histological analysis) at 3 or 6 months after IVD lesion and naïve controls for histological analysis of muscle, adipose and connective tissue cross sectional areas (CSA), and immunohistochemistry to study muscle fiber types. Real-time polymerase chain reactions quantified expression of TNF, IL-1β and TGF-β1. RESULTS.: MSC-treatment of IVD lesion prevented the increased adipose and connective tissue CSA expected after IVD lesion. MSC-treatment did not prevent slow-to-fast muscle fiber type transformation. Gene expression of pro-inflammatory cytokines within the muscle was altered by the MSC-treatment of IVD. Increased IL-1β expression was prevented in the early treatment group and TNF and TGF-β1 expression was upregulated at 6 months. CONCLUSION.: Results show that although MSC-treatment prevents fatty infiltration and fibrosis of the multifidus muscle after IVD lesion, it cannot prevent a muscle inflammatory response and muscle fiber transformation. These findings highlight the potential role of MSC therapy after IVD injury, but reveals that other interventions may also be necessary to optimize recovery of muscle.Level of Evidence: 4 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
News Article | November 2, 2016
The latest report from business intelligence provider visiongain offers comprehensive analysis of the global empty capsule market. The global empty capsules market was valued at $1,360m in 2015. Visiongain forecasts this market to increase to $1,944m in 2020. The market will then continue to increase to $3,074m in 2026, growing at a CAGR 6.8% between 2020 and 2026. How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new report you find 298-page report you will receive 129 in-depth tables and 71 figures - all unavailable elsewhere. The 286 page report provides clear detailed insight into the global empty capsules market. Discover the key drivers and challenges affecting the market. By ordering and reading our brand new report today you stay better informed and ready to act. To see a report overview please email Sara Peerun on firstname.lastname@example.org • Revenue forecasts to 2026 are provided for the following segments in the empty capsules market, by type of raw material: - Gelatin Capsules • Pig Skin Gelatin • Bovine Derived Gelatin • Bone Meal Gelatin • Others - Non-gelatin Capsules • Hydroxypropyl Methyl Cellulose (HPMC) • Pullulan & Starch Material • Revenue forecasts to 2026 are provided for the following segments in the empty capsules market, by therapeutic application: • Antibiotic and Antibacterial Drugs • Vitamins and Dietary Supplements • Cough and Cold Preparations • Anti-inflammatory Drugs • Cardiovascular Drugs • Antacid and Antiflatulent Drugs • Antianaemic Drugs • Others • Revenue forecasts to 2026 are provided for the following segments in the empty capsules market, by end user: • Pharmaceutical industry • Neutraceutical Industry • Cosmetics Industry • Clinical Research Laboratories • Analysis of the key factors driving growth in the global, regional and country level of the Empty Capsules Market from 2016-2026 • Provides market share analysis of key players operating in the empty capsules market Visiongain's study is intended for anyone requiring commercial analyses for the Empty Capsules Market and leading companies. You find data, trends and predictions. To see a report overview please email Sara Peerun on email@example.com To request a report overview of this report please emails Sara Peerun at firstname.lastname@example.org or call Tel: +44 (0) 20 7336 6100 To see a report overview please email Sara Peerun on email@example.com